Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Padnarsertib - Karyopharm Therapeutics

Next Previous
Search
Drug Profile

Padnarsertib - Karyopharm Therapeutics

Alternative Names: ATG-019; KPT-9274

Latest Information Update: 20 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Antengene Corporation; Karyopharm Therapeutics
  • Class Amides; Amines; Antineoplastics; Benzofurans; Fluorinated hydrocarbons; Fluorobenzenes; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors; P21 activated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma; Rhabdomyosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ewing's sarcoma; Neuroendocrine tumours; Rhabdomyosarcoma
  • No development reported Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 31 Dec 2024 Preclinical trials in Ewing's Sarcoma in USA (PO)
  • 31 Dec 2024 Preclinical trials in Rhabdomyosarcoma in USA (PO)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top